Multiple myeloma
Conditions
Interventions
1.Rd therapy (1-10 cycle): Lenalidomide from day 1 to day 21 and dexamethasone at day 1, 8, 15 and 22 are administered (10 cycles, every 28 days) 2.Rd+Bor therapy (8 cycles): Bortezomib is addition
Sponsors
Cooperative study between the West Japan Hematology Study Group and Clinical Research Support Center Kyushu
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Primary enrollment inclusion criteria 1) Patients are >= 20 years of age 2) Patients who understand the informed consent and can sign the informed consent form by his/her free will. 3) Patients who obey the protocol visit and other rules. 4) Newly diagnosed multiple myeloma. 5) Patients with following measurable M protein by protein electrophoresis analysis 6) Patients who cannot carry out hematopoietic stem cells transplantation. 7) ECOG PS 0, 1 or 2 8) Female childbearing patients who meet the following requirements Patients who can agree to receive two times of pregnancy test before study drug administration Patients who can agree to refrain completely from the sex with her partner or be effective contraception measures 28 days before study drug administration, during treatment period and 28 days after discontinuation of study drug administration. 9) Male patients who meet the following requirements: Patients who can agree to completely refrains from the sex with his partner. 28days after discontinuation of study drug administration. Patients who agree to not provide a seminal fluid and a sperm during treatment period and 28 days after the discontinuation of study drug administration. 10) Patients who meet the following requirements: Understand the risk of teratogenicity of lenalidomide. Can agree to not donate blood during the study drug administration and 28 days after study drug administration. Secondary enrollment inclusion criteria 1) MM patients meeting all of the following three definitions. Monoclonal bone marrow plasma cells >=10% or biopsy-proven plasmacytoma Monoclonal protein (M protein) in serum or urine any one or more of the following (1) and (2): (1) Myeloma-related evidence of end organ damage Hypercalcemia,Renal insufficiency,Anemia,Osteolytic lesion or osteoporosis (2) Any one or more of the following definition. 60% or greater monoclonal plasma cells on bone marrow examination Serum Free Light Chain >= 100 More than 2 focal lesions on MR
Exclusion criteria
Exclusion criteria: Primary enrollment exclusion criteria 1) Patients with severe disorder, laboratory test abnormality, mental disease. 2) Patient having a severe disease thought to be exposed to unacceptable risks if he/she participates in the study. 3) Patients who are in a state with the possibility to have an influence on the interpretation of the study data. 4) Patients with treatment history of myeloma. 5) Female patients with pregnancy or nursing. 6) Patients with following laboratory test abnormality. Neutrophil < 1000/mm3 Platelet before transfusion < 50,000/mm3 (7 days passed after platelet transfusion) AST or ALT > 3 X ULN 7) Patients with renal failure needed for hemodialysis or peritoneal dialysis. 8) Patients with anamnesis of malignant tumor other than MM 9) Patients who are or will not received antithrombotic therapy. 10) Patients with grade 2 or more peripheral neuropathy. 11) Patients with incontrollable systemic fungal/bacterial/viral infection 12) Patients with primary amyloidosis (AL) (immunoglobulin light chain) or myeloma with amyloidosis. 13) Patients not receiving dexamethasone or with contraindication of dexamethasone. 14) Patients not receiving bortezomib or with contraindication of bortezomib. Secondary enrollment exclusion criteria 1) Patients met exclusion criteria after primary enrollment. 2) Patient who are confirmed for human immunodeficiency virus (HIV)-positive or treated. 3) Patients with hepatitis B virus (HBs antigen) positive or hepatitis C virus (HCV) antibody positive (if HBc antibody or HBs antibody is positive even if HBs antigen is negative, hepatitis B virus (HBV) DNA test is carried out. If HBV DNA is detected, The patients are excluded) 4) Any other patients who are regarded as unsuitable for this study by the investigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete response (CR) rate up to 18 cycles | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. CR rate in the patients with additional administration of bortezomib. 2. Response rate up to 18 cycles. 3. Incidence of adverse events up to 18 cycles. 4. Progression free survival (PFS) 5. Overall survival (OS) 6. Progression free survival from enrollment to progression or death after second line regimen (judged by investigator)(PFS2) 7. Best response in second line regimen. 8. Evaluation of immune dynamics (degree of immune activation) 9. Evaluation of QOL. | — |
Countries
Japan
Contacts
Public ContactHirohiko Shibayama
Osaka University Graduate School of Medicine Department of Hematology and Oncology
Outcome results
None listed